medigraphic.com
ISSN 3061-8142 (Electronic)
ISSN 0484-7903 (Print)

2013, Number 3

<< Back Next >>

Rev Mex Anest 2013; 36 (3)

Malignant hyperthermia. Current concepts

Carrillo-Esper R, Lázaro-Santiago G, Nava-López JA

Language: Spanish
References: 25
Page: 185-192
PDF size: 232.71 Kb.


ABSTRACT

Malignant hyperthermia is a pharmacogenetic musculoskeletal disorder. Patients with malignant hyperthermia experience exaggerated metabolic response when exposed to certain triggers such as volatile anesthetics and succinylcholine. The incidence of malignant hyperthermia ranges from 1:5,000 to 1:50,000-100,000 anesthetics procedures. The classic clinical presentation of malignant hyperthermia include hyperthermia, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, muscle rigidity and rhabdomyolysis. The pathophysiologic changes of malignant hyperthermia are due to uncontrolled elevation of mioplasmic calcium. In most cases, the syndrome is caused by a defect of the ryanodine receptor. Dantrolene sodium is a specific antagonist of the pathophysiologic changes. The Malignant Hyperthermia Association of the United States recommends the caffeine/halothane testing as the most definitive test for malignant hyperthermia susceptibility. The aim of this paper is to review current concepts related to this entity.


REFERENCES

  1. Kim D. Malignant Hyperthermia. Korean J Anesthesiol. 2012;63:391-401.

  2. Bandschapp O, Girard T. Malignant Hyperthermia. Swiss Medical Weekly. 2012;142:1-4.

  3. McCarthy E. Malignant hyperthermia, pathophysiology, clinical presentation and treatment. AACN Clinical Issues. 2004;15:231-237.

  4. Patil P, Pradesh U. Malignant hyperthermia in the oral and maxillofacial surgery patient: an update. OOOOE. 2011;112:e1-e7.

  5. Correia AC, Silva PC, da Silva BA. Malignant Hyperthermia: Clinical and Molecular aspects. Rev Bras Anestesiol. 2012;62:820-837.

  6. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:1-14.

  7. Elías G, Venegas A. Hipertermia Maligna. Acta Pediátrica de México. 1996;17:45-48.

  8. Benkusky N, Farrell E, ValdiviaH. Ryanodine receptor channelopathies. Biochem Biophys Res Commun. 2004;322:1280-1285.

  9. Denborough M. Malignant hyperthermia. Lancet. 1998;352:1131-1136.

  10. Rosenberg H, Rueffert H. Clinical utility gene card for: malignant hyperthermia. Eur J Hum Genet. 2011;19:1-4.

  11. Petegem F. Ryanodine Receptors: Structure and Function. J Biol Chem. 2012;287:31624-31632.

  12. Lanner J, Georgiou D, Joshi A, Hamilton S. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010;2:1-21.

  13. Anderson A, Brown R, Polster B, Pollock N, Stowell K. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology. 2008;108:208-215.

  14. Correia A, Silva P, Silva B. Hipertermia maligna: Aspectos moleculares y clínicos. Rev Bras Anestesiol. 2012;62:1-10.

  15. Gurnaney H, Brown A, Litman R. Malignant hyperthermia and muscular dystrophies. Anesth Analg. 2009;109:1043-1048.

  16. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg. 2009;109:1049-1053.

  17. Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins P. Core Myopathies and Risk of Malignant Hyperthermia. Anesth Analg. 2009;109:1167-73.

  18. Metterlein T, Schuster F, Tadda L, Hager M, Roewer N, Anetseder M. Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals. Cardiovasc Ther. 2010;28:356-360.

  19. Hopkins P. Malignant Hyperthermia: pharmacology of triggering. BJA. 2011;107:48-56.

  20. Wappler F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010;23:417-422.

  21. Driessen J. Neuromuscular and Mitochondrial disorders: what is relevant to the Anesthesiologist? Curr Opin Anaesthesiol. 2008;21:350-355.

  22. Hirshey Dirksen SJ, Larach MG, Rosenberg H, Brandom BW, Parness J, Lang RS, et al. Special article: Future directions in malignant hyperthermia research and patient care. Anesth Analg. 2011;113:1108-1119.

  23. Christiansen L, Collins K. Pathologic findings in malignant hypertermia. A case report and review of literature. Am J Forensic Med Pathol. 2004;25:327-333.

  24. Available: http://www.mhaus.org

  25. Available: http://www.bmha.co.uk




2020     |     www.medigraphic.com